The Potential Drug Interactions Between Multiple Sclerosis and COVID-19 Therapies

Turkish Journal of Pharmaceutical Sciences

article

Cansu GÖNCÜOĞLU¹  Aygin BAYRAKTAR EKİNCİOĞLU¹  Aslı TUNCER² 

[1] Hacettepe University Faculty of Pharmacy, Department of Clinical Pharmacy;Hacettepe University Faculty of Medicine, Department of Neurology

关键词: Multiple sclerosis;    COVID-19;    disease-modifying therapy;    interaction;   

DOI  :  10.4274/tjps.galenos.2021.92892

来源: Galenos Yayinevi

【 摘 要 】

Since December 2019, the coronavirus disease-2019 (COVID-19)has spread rapidly all over the world and has severely affectedthe elderly population and patients with comorbidities. Druginteractions with agents used in the treatment of multiplesclerosis (MS) such as interferon beta, glatiramer acetate,ocrelizumab, natalizumab, and alemtuzumab are rare. Therefore,interactions between disease-modifying therapies (fingolimod,teriflunomide, dimethyl fumarate, and cladribine) and COVID-19drugs1 are outlined in this letter.

【 授权许可】

Unknown